Is Urinary NGAL Determination Useful for Monitoring Kidney Function and Assessment of Cardiovascular Disease? A 12-Month Observation of Patients with Type 2 Diabetes
Table 3
Characteristics of 30 T2DM patients with available follow-up data at the beginning of the study (baseline results) and after 12-month follow-up (control results).
Baseline results
Control results
BMI, kg/m2
30.9 ± 5.5
31.4 ± 5.7
0.6
, %
7.98 ± 1.99
6.31 ± 0.93
0.037
Hemoglobin, g/dL
14.2 ± 1.4
13.9 ± 1.4
0.019
WBC, 103/μL
7.59 ± 2.39
7.34 ± 2.67
0.5
Total cholesterol, mmol/L
5.38 (4.11–5.95)
4.78 (4.01–5.86)
0.3
LDL-cholesterol, mmol/L
3.10 (2.07–3.75)
2.62 (1.98–3.94)
0.3
HDL-cholesterol, mmol/L
1.32 (1.01–1.53)
1.36 (1.03–1.49)
0.1
Triglycerides, mmol/L
1.57 (1.13–1.89)
1.53 (1.16–2.03)
0.5
Serum creatinine, μmol/L
68.1 (60.1–76.9)
69.0 (61.9–77.8)
0.035
eGFR, mL/min/1.73 m2
94.4 (79.7–98.3)
87.0 (74.6–99.0)
0.023
Albuminuria, mg/L
8.53 (6.59–13.53)
5.55 (2.14–19.75)
0.2
uACR, mg/g
7.49 (3.39–13.38)
4.69 (2.86–43.41)
0.1
uNGAL, μg/L
18.00 (9.00–32.20)
9.35 (2.50–19.30)
0.018
uNCR, μg/g
16.18 (10.00–33.72)
8.82 (3.09–26.83)
0.037
Leukocyturia,
3 (10)
5 (17)
0.4
LDL, low-density lipoprotein; HDL, high-density lipoprotein; see Table 1.
